Dec 27 (Reuters) - PainReform Ltd :
* PAINREFORM PROVIDES FURTHER UPDATE ON PHASE 3 CLINICAL TRIAL OF PRF-110
* PAINREFORM LTD: DATA FROM FINAL 24-HOUR PERIOD COULD NOT BE CLARIFIED TO SATISFY STUDY'S PRIMARY ENDPOINT 72 HOURS REQUIREMENT
* PAINREFORM LTD: DATA FROM FINAL 24-HOUR PERIOD DID NOT MEET PRIMARY ENDPOINT OF STUDY
* PAINREFORM LTD - INITIATES RESEARCH AND DEVELOPMENT ACTIVITIES TO REFINE PHARMACO-KINETICS AND PHARMACO-DYNAMICS OF PRF-110
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.